One-year CALM Outcomes: Data From a Real-world Registry Study of the 0.18-mg Fluocinolone Acetonide Intravitreal Implant for the Treatment of Patients With Non-infectious Uveitis Affecting the Posterior Segment

Background and Objective: The CALM Registry was a retrospective cohort study that assessed real-world outcomes of treating chronic noninfectious uveitis affecting the posterior segment (NIU-PS) with the 0.18-mg fluocinolone acetonide implant (FAi). Patients and Methods: Eligible participants were aged ≥18 years and diagnosed with chronic NIU-PS. Safety and effectiveness outcomes, as available, were collected from charts. Results: Two hundred sixty-seven eyes from 200 participants received the FAi (mean age, 62.8 years; 10.5% phakic). Median intraocular pressure remained stable at 14.0 mmHg. Two cataract surgeries were reported. In the 12 months pre-FAi, 84.1% of eyes had ≥1 recurrence of uveitis; 12 months post-implant, the recurrence rate was 12.0%, and retinal thickness reduced significantly ( P < .05). The proportion of eyes with ≥ 20/40 visual acuity was stable from baseline (49%) to 12 months (55%). Conclusion: Real-world data from the CALM Registry study indicate effective control of chronic NIU-PS with the FAi and no new safety signals.